EARLY MOVERS: Kohl's shares take a beating after holiday sales disappoint, while Bed Bath & Beyond continues to shine

Also in the frame in pre-market is another retailer - Target Corp - and house builder KB Home

Kohl's shares tanked in pre-market New York trade

Retailers were in focus and Kohl's Corp (NYSE:KSS) shares tanked over 5% in pre-market as the big-cap retailer raised its full-year profit outlook but reported a slowdown in holiday-period sales.

Same-store sales for the November to December last year rose 1.2% from a year ago, but that was compared with growth of 6.9% in the same period last year, said the Wisconsin-based group.

Shares plunged 5.44% to $66.10.

Also in retail, Target Corp (NYSE:TGT) shares shed 1.62% to $69.15 before the bell, despite posting stronger-than-expected holiday sales and revealing it would see double-digit adjusted earnings growth for the 2019 fiscal year.

Target said same-store sales for the two months ending December last year increased by 5.7%, which was ahead of the 3.4% pace recorded over the same period last year.

Target also told investors Thursday that Cathy Smith will retire as the chief financial officer (CFO), and move to an advisory role within the group from May 2020.

Bed Bath & Beyond Inc (NASDAQ:BBBY) continued north on Thursday, having risen over 4% yesterday. Shares are today up 14.6% in pre-market at $14.05.

It came as the home goods firm said it was ahead of its long-term financial goals in its quarterly earnings. This statement covers the slowing of declines in operating profit and net earnings per share (EPS), as well as increasing net earnings per share by 2020.

KB Home (NYSE:KBH), the housebuilder, saw shares add 4.19% in pre-market to $22.90 as the firm beat expectations in its quarterly earnings.

The company earned $0.96 per share, while analysts had expected $0.93 per share. Its revenue was in line, at $1.35 billion.

Constellation Brands Inc (NYSE:STZ) added 2.83% to $155.21 in pre-market deals, having tumbled 12.5% yesterday.

The group posted an outlook for the year which missed expectations, dented by higher interest expenses.

The New York-headquartered group said it expects to earn between $9.20 and $9.30 per share for its 2019 fiscal year on an adjusted basis, while scribes on Wall Street had expected $9.43 per share.

After the disappointing outlook, CEO Rob Sands told CNBC's Jim Cramer that the share decline had made the stock absolutely fantastic value.

He said the drop after earnings was a "total overreaction".

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 4 hours ago

2 min read